UBS Raises JD HEALTH (06618) Target Price to HK$85 on Strong Revenue Growth and Rising Profit Margins

Stock News

Nov 17, 2025

UBS has upgraded its profit forecasts for JD HEALTH (06618) by 4% to 13% for 2025–2027, raising the target price from HK$78.5 to HK$85 based on a 30x P/E ratio or adjusted earnings for FY2027. The new target implies a 1.25x PEG ratio for 2027, with a maintained "Buy" rating.

The bank noted that JD HEALTH outperformed expectations in both revenue and profit for Q3 this year, with revenue growth accelerating to 28.7% YoY from 24.5% in H1. This was attributed to robust growth in pharmaceutical sales, a significant rebound in health supplement sales, and a relatively low base in Q3 2024.

UBS highlighted that JD HEALTH's pharmaceutical segment remains strong, supported by steady progress in its online-to-offline (O2O) strategy. The bank estimates drug sales grew around 30% YoY in Q3, with chronic disease and innovative drugs expanding even faster.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1165425393"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165425393\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165425393?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165425393","market":"sg","top_or_hot":-1,"title":"UBS Raises JD HEALTH (06618) Target Price to HK$85 on Strong Revenue Growth and Rising Profit Margins","media":"Stock News","content":"<p>UBS has upgraded its profit forecasts for JD HEALTH (06618) by 4% to 13% for 2025–2027, raising the target price from HK$78.5 to HK$85 based on a 30x P/E ratio or adjusted earnings for FY2027. The new target implies a 1.25x PEG ratio for 2027, with a maintained \"Buy\" rating.</p>\n<p>The bank noted that JD HEALTH outperformed expectations in both revenue and profit for Q3 this year, with revenue growth accelerating to 28.7% YoY from 24.5% in H1. This was attributed to robust growth in pharmaceutical sales, a significant rebound in health supplement sales, and a relatively low base in Q3 2024.</p>\n<p>UBS highlighted that JD HEALTH's pharmaceutical segment remains strong, supported by steady progress in its online-to-offline (O2O) strategy. The bank estimates drug sales grew around 30% YoY in Q3, with chronic disease and innovative drugs expanding even faster.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Raises JD HEALTH (06618) Target Price to HK$85 on Strong Revenue Growth and Rising Profit Margins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Raises JD HEALTH (06618) Target Price to HK$85 on Strong Revenue Growth and Rising Profit Margins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has upgraded its profit forecasts for JD HEALTH (06618) by 4% to 13% for 2025–2027, raising the target price from HK$78.5 to HK$85 based on a 30x P/E ratio or adjusted earnings for FY2027. The new target implies a 1.25x PEG ratio for 2027, with a maintained \"Buy\" rating.</p>\n<p>The bank noted that JD HEALTH outperformed expectations in both revenue and profit for Q3 this year, with revenue growth accelerating to 28.7% YoY from 24.5% in H1. This was attributed to robust growth in pharmaceutical sales, a significant rebound in health supplement sales, and a relatively low base in Q3 2024.</p>\n<p>UBS highlighted that JD HEALTH's pharmaceutical segment remains strong, supported by steady progress in its online-to-offline (O2O) strategy. The bank estimates drug sales grew around 30% YoY in Q3, with chronic disease and innovative drugs expanding even faster.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1165425393","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165425393","pubTimestamp":1763372775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has upgraded its profit forecasts for JD HEALTH (06618) by 4% to 13% for 2025–2027, raising the target price from HK$78.5 to HK$85 based on a 30x P/E ratio or adjusted earnings for FY2027. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK1583":"高瓴概念","BK1571":"互联网医疗","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1589":"北水核心资产","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1515":"抗疫概念","06618":"京东健康","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1142":"互联网与直销零售","LU0051755006.USD":"摩根大通中国A (dist)","BK1591":"就地过年概念","BK1615":"港股-互联网","BK1247":"药品零售"},"translate_title":"瑞银上调京东健康(06618)目标价至85港元收入增长强劲利润率上升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":1,"06618":1},"content_text":"UBS has upgraded its profit forecasts for JD HEALTH (06618) by 4% to 13% for 2025–2027, raising the target price from HK$78.5 to HK$85 based on a 30x P/E ratio or adjusted earnings for FY2027. The new target implies a 1.25x PEG ratio for 2027, with a maintained \"Buy\" rating.\nThe bank noted that JD HEALTH outperformed expectations in both revenue and profit for Q3 this year, with revenue growth accelerating to 28.7% YoY from 24.5% in H1. This was attributed to robust growth in pharmaceutical sales, a significant rebound in health supplement sales, and a relatively low base in Q3 2024.\nUBS highlighted that JD HEALTH's pharmaceutical segment remains strong, supported by steady progress in its online-to-offline (O2O) strategy. The bank estimates drug sales grew around 30% YoY in Q3, with chronic disease and innovative drugs expanding even faster.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}